Topotecan trials for Lung cancer

All Topotecan trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Topotecan for Lung cancer

• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
  NCT07099898 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 132 locations
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06954246 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
  NCT07365241 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 63 locations
• ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
  NCT06498479 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
  NCT06496048 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
  NCT07189455 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
  NCT06128837 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
  NCT06801834 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 220 locations
• Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
  NCT05874401 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Topotecan for Lung cancer?

12 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.